Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Mellanox Technologies (NASDAQ: MLNX ) lost nearly 13% of their value today despite beating expectations last night. Analysts at two investment firms are not at all convinced that last night's good news will translate into long-term strength.
So what: Mellanox reported $83.1 million in revenue and earnings of $0.10 per share, beating the top-line consensus of $80.9 million and the bottom-line consensus of $0.04 per share. However, revenues declined by 6% year over year. This should be ameliorated somewhat by Mellanox's guidance of 14% revenue growth from first to second quarter -- equal to a strong $94.7 million in revenue. Analysts at Needham, in downgrading Mellanox to "hold" from "buy," disliked Mellanox's lack of clarity and the "lumpiness" in Mellanox's business model, which tends to be erratic from quarter to quarter. Mizuho Securities downgraded the company from "buy" to "hold," citing a lack of upside catalysts and a high valuation relative to its peer group.
Top Life Sciences Stocks To Own Right Now: Silicon Laboratories Inc.(SLAB)
Silicon Laboratories Inc., a fabless semiconductor company, designs, develops, and markets analog-intensive and mixed-signal integrated circuits (ICs). The company offers broad-based products, which include microcontrollers, clocks and oscillators, wireless transceivers, digital isolators and related products, and human interface sensors and controllers; broadcast products comprising radio receivers and transmitters, and video tuners and demodulators; and access products consisting of embedded modems, subscriber line interface circuits, Voice over IP (VoIP) products, and power over Ethernet devices, as well as DSL analog front end ICs and IRDA devices. It provides ICs for use in various electronic applications, such as portable devices, AM/FM radios, and other consumer electronics, as well as networking, test and measurement, industrial monitoring and control, and customer premises equipment. The company markets its products through direct sales force, and through a networ k of independent sales representatives and distributors in the United States, Taiwan, China, South Korea, Japan, and internationally. Silicon Laboratories Inc. was founded in 1996 and is headquartered in Austin, Texas.
Advisors' Opinion:- [By Garrett Cook]
In trading on Friday, technology shares were relative laggards, down on the day by about 0.80 percent. Top decliners in the sector included Silicon Laboratories (NASDAQ: SLAB), down 15.32 percent, and Informatica (NASDAQ: INFA), off 11.91 percent.
- [By MONEYMORNING.COM]
XSD holds such big-cap names as Texas Instruments Inc. (Nasdaq: TXN) and Intel Corp. (Nasdaq: INTC). It also owns Atmel Corp. (Nasdaq: ATML), which has a market cap of less than $4 billion, and Silicon Laboratories Inc. (Nasdaq: SLAB), with a market cap of $2 billion.
- [By Rich Smith]
Austin, Texas-based Silicon Laboratories (NASDAQ: SLAB ) , which chose a new chief financial officer last month, has now found him a bit of extra work to do.
- [By Garrett Cook]
In trading on Friday, technology shares were relative laggards, down on the day by about 0.80 percent. Top decliners in the sector included Silicon Laboratories (NASDAQ: SLAB), down 13.7 percent, and Informatica (NASDAQ: INFA), off 13.4 percent.
Top 5 Tech Companies For 2014: Synergy Pharmaceuticals Inc (SGYP)
Synergy Pharmaceuticals, Inc., incorporated on February 11, 1992, is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company�� lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company�� active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors.
As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor. As of December 31, 2011, the Company was dosing patients in an 800-patient Phase II/III clinical trial of plecanatide to treat. It is also developing a second generation GC-C receptor analog, SP-333, which is in pre-clinical development for the treatment of gastrointestinal inflammatory diseases. SP-333 is a synthetic analog of uroguanylin, a natriuretic hormone.
The Company competes with Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., Takeda Pharmaceuticals America, Inc., Sucampo Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc. and Shire Plc.
Advisors' Opinion:- [By Sean Williams]
Finally, Synergy Pharmaceuticals (NASDAQ: SGYP ) may have had the wildest week of them all. Synergy's share price spiked 16% on Tuesday as an analyst at Cantor Fitzgerald raised her peak sales estimate for plecanatide, the company's midstage drug for chronic idiopathic constipation and irritable bowel syndrome with constipation, to $1.58 billion from $1.05 billion, as clinical data has been stronger than expected. However, the company didn't return the favor to shareholders by -- the very next day, mind you ��announcing a secondary offering of 16.375 million shares. The downside of clinical-stage companies is the always apparent risk of dilution. Shares have lost 25% since their Tuesday close.
- [By Monica Gerson]
Breaking news
Time Warner Cable (NYSE: TWC) reported a drop in its third-quarter profit. Time Warner Cable's quarterly profit fell to $532 million, or $1.84 per share, from $808 million, or $2.60 per share, in the year-ago period. To read the full news, click here. Synergy Pharmaceuticals (NASDAQ: SGYP) today announced the start of a phase 2 clinical trial to evaluate the safety and efficacy of SP-333, its second-generation GC-C agonist and once-daily oral treatment, in adult patients with opioid-induced constipation (OIC). To read the full news, click here. Cigna (NYSE: CI) reported a 19% rise in its third-quarter earnings and lifted its full-year earnings outlook. To read the full news, click here. Charm Communications (NASDAQ: CHRM) announced today that the special committee of the Company's board of directors, consisting of independent directors Mr. Zhan Wang, Mr. Andrew J. Rickards and Mr. Gang Chen, has retained China Renaissance Securities (Hong Kong) Limited as its financial advisor and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP as its legal advisor. To read the full news, click here.Posted-In: Bank of America US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets
Top 5 Tech Companies For 2014: Juniper Networks Inc (JNPR)
Juniper Networks, Inc. (Juniper Networks), incorporated on September 10, 1996, designs, develops, and sells products and services that together provide its customers with network infrastructure. It operates in two segments: Infrastructure and Service Layer Technologies (SLT). The Company�� Infrastructure segment primarily offers routing and switching products that are used to control and direct network traffic from the core, through the edge, aggregation, and the customer premise equipment level. Infrastructure products include its Internet protocol (IP) routing, carrier Ethernet routing portfolio, and Ethernet switching portfolio. In addition, the Infrastructure segment offers a complete wireless local area network (WLAN) solution. Its SLT segment offers solutions that meet a range of its customers' priorities, from protecting the users, applications and data on the network itself to providing network services across a distributed infrastructure. Effective September 13, 2013, Juniper Networks, Inc. acquired Contrail Networks Inc.
Brilliant is a supplier of packet-based, network synchronization equipment and monitoring solutions. During the year ended December 31, 2011, the Company introduced its network architecture and fabric technology for the data center, QFabric. It serves the high-performance networking requirements of global service providers, enterprises, and public sector organizations. The Company�� open cross-network software platform includes the Junos operating system (Junos OS), Junos Space network application platform, and Junos Pulse integrated network client. The Company offers a product portfolio that spans routing, switching, security, application access, and mobility device security.
Infrastructure Products
The Company�� T Series core routers are primarily designed for core IP infrastructures and are also being sold into the multi-service environment. Its PTX Series is a large capacity (8 and 16 tera-bits per second) MPLS-optimized packe! t transport switch for the core networks, of content service providers and Tier 1 service providers, with high throughout of packet traffic. The Company�� E Series products are a full featured platform designed for the network edge with support for carrier-class routing, broadband subscriber management services, and a set of IP services. The MX Series is a product family developed to address emerging Ethernet network architectures and services in service provider and enterprise networks. The Company�� EX Series family extends its product portfolio running its Junos OS to address the Ethernet switch market. Ethernet is a used technology, which is used to transport information in enterprise networks. Infrastructure Products also includes QFabric Products and WLAN product.
SLT Products
SLT Products include Services Gateway, Integrated Firewall, and VPN Solutions, Secure Access Appliances, Secure Access Appliances, IDP Series Appliances and Identity and Policy Control Solutions. The Company�� SRX Series of dynamic services gateways, running its Junos software, provides firewall/VPN and combines routing, switching, and security functionality. The series is designed to meet network and security requirements for data center consolidation, rapid managed services deployments, and aggregation of security services. Its firewall and VPN systems and appliances are designed to provide integrated firewall, VPN, and denial of service protection capabilities for both enterprise environments and service provider network infrastructures. These products range from its SSG product series, which combines LAN/WAN routing capabilities with threat management features, such as antivirus, anti-spam, and Web filtering technologies, to its ISG and NetScreen Series firewall and VPN systems, which are designed to deliver security in medium/large enterprises, carrier networks, and data centers.
The Company�� Junos Pulse, Junos Pulse Mobile Security Suite, and SA Series SSL VPN appliances,! designed! for use in companies of all sizes, are used to provide secure access to corporate resources for remote and mobile users from any Web-enabled device, regardless of location. Its portfolio of identity and policy control solutions integrates subscriber privileges, application requirements, and business policies with the IP network infrastructure.
The Company competes with Cisco Systems, Inc. (Cisco), Alcatel-Lucent, Brocade Communications Systems, Inc. (Brocade), Extreme Networks, Inc., Hewlett Packard Company (HP), Huawei Technologies Co., Ltd. (Huawei), Check Point Software Technologies, F5 Networks, Inc., Palo Alto Networks, Inc., and Riverbed Technology, Inc.
Advisors' Opinion:- [By Wallace Witkowski]
Shares of Juniper Networks Inc. (JNPR) �fell 1.3% to $20.10 on moderate volume after the networking gear company reported third-quarter results and provided a outlook for the current quarter.
- [By Dan Caplinger]
Investors shouldn't automatically conclude that the problem is specific to Riverbed, though. Networking peer F5 Networks (NASDAQ: FFIV ) had to give unfavorable revenue guidance for the remainder of the year when it released its own earnings earlier this week. Moreover, Juniper Networks (NYSE: JNPR ) sported falling sequential revenue, and guided the current quarter toward the low end of sales expectations. A tough spending environment has made it hard for any networking players to hold their own.
- [By Jonas Elmerraji]
2014 has been a rough year for shareholders in Juniper Networks (JNPR). Since shares peaked in January, this stock has dropped to the tune of 17%. The bad news is that this stock isn't showing any signs of ending that selloff. The good news is that you don't have to be an expert technical trader to figure out what's going on here.
The price action in Juniper Networks is about as simple as it gets. JNPR has been bouncing its way lower in a textbook downtrending channel since last September, swatted lower on each successive test of trend line resistance. That pair of parallel trend lines on Juniper's chart defined the high-probability range for shares of JNPR to trade within. And since those lines are pointing down and to the right, it makes sense to stay out of this stock in August. It's really just as simple as that.
I'd recommend staying away from the long-side of JNPR until shares can press up through their 50-day moving average, a level that's been a good proxy for trend line resistance on the way down. Until that happens, the downtrend is intact.
Read More: 5 Hated Earnings Stocks You Should Love
Top 5 Tech Companies For 2014: Ebix Inc(EBIX)
Ebix, Inc. provides on-demand software and e-commerce solutions to the insurance industry. The company operates data exchanges, which connects multiple entities within the insurance markets and enables the participant to carry and process data from one end to another in the areas of life insurance, annuities, employee health benefits, risk management, workers compensation, and property and casualty (P&C) insurance. It is also involved in designing and deploying broker systems comprising three back-end systems consisting of eGlobal for multinational P&C insurance brokers; WinBeat for P&C brokers in the Australian and New Zealand markets; and EbixASP for the P&C insurance brokers in the United States. In addition, the company offers business process outsourcing services, which include certificate origination, certificate tracking, claims adjudication call center, and back office support. Further, it focuses on designing and deploying on-demand and back-end carrier systems, s uch as Ebix Advantage and Ebix Advantageweb targeted at small, medium, and large P&C carriers in the United States and internationally that operate in the personal, commercial, and specialty line areas of insurance. Additionally, Ebix, Inc. provides software development, customization, and consulting services to various companies in the insurance industry, such as carriers, brokers, exchanges, and standard making bodies. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Atlanta, Georgia.
Advisors' Opinion:- [By MONEYMORNING.COM]
Ebix Inc. (Nasdaq: EBIX) has its shares floated at a very high 47.1%, and they took a 14% hit this past month. EBIX supplies management software to the insurance industry. It has been in the crosshairs of the short sellers for more than a year now, since short selling firm Gotham Research LLC targeted what it called unreliable, inaccurate, and incomplete accounting in March 2013 and sustained that attack into September. It has since been the subject of SEC probes and civil litigation, and even took heat for alleged money laundering in its cross-border transactions. These lingering legal troubles ultimately derailed a merger agreement with Goldman Sachs & Co. (NYSE: GS) last summer, where GS had valued the company at $820 million.
- [By Eric Volkman]
Ebix (NASDAQ: EBIX ) will be very busy in the near future doing work for a major South American telecom incumbent. The company announced that it has signed a deal with Telefonica's (NYSE: TEF ) Brazilian subsidiary Telefonica/Vivo (NYSE: VIV ) , also known as Telefonica Brasil,�to supply its services for the latter's eHealth Self Care initiative, which aims "to provide health assistance and complimentary services to their millions of clients." Ebix will utilize its A.D.A.M. Health Content Exchange solution to make this happen.
- [By Taylor Muckerman]
Better watch your book
Ebix� (NASDAQ: EBIX ) , an insurance software company, has been under investigation since last November but had denied these allegations initially. Just 13 days ago, an acquisition deal was called off by an arm of Goldman Sachs after further investigations were announced by the U.S. Attorney for the Northern District of Georgia. The stock reacted to the announcement by dropping 44% and 13% in the two days following as investors sold off. This reaction is justified in the fact that the probe surrounds alleged accounting misconduct. - [By Dan Caplinger]
Beyond the Dow, insurance-software maker Ebix (NASDAQ: EBIX ) soared more than 10% after news that Goldman Sachs (NYSE: GS ) had offered, through an affiliate, to take the company private in a deal worth $20 per share. Given the fact that shares closed at $20.60 today, investors apparently believe the offer is too low, and expect a bidding war for the company. Given the huge opportunity that Obamacare is giving Ebix to ramp up its business, shareholders are likely right to demand more for their stock.
No comments:
Post a Comment